MyoKardia, Inc. (MYOK)

Home » Stocks » MYOK

Nov 16, 2020 - MYOK was delisted after being acquired by BMY

Stock Price: $224.91 USD 0.00 (0.00%)

Updated Nov 17, 2020 4:00 PM EST

• Overview
• News
• Financials

Key Info

Market Cap	11.99B
Revenue (ttm)	12.40M
Net Income (ttm)	-276.96M
Shares Out	53.32M
EPS (ttm)	-5.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	Nov 17, 2020
Last Price	$224.91
Previous Close	$224.91
Change ($)	0.00
Change (%)	0.00%
Day's Open	-
Day's Range	224.52 - 225.00
Day's Volume	0
52-Week Range	42.65 - 225.00

More Stats

Market Cap	11.99B
Enterprise Value	11.15B
Earnings Date (est)	n/a
Ex-Dividend Date	n/a
Shares Outstanding	53.32M
Float	51.76M
EPS (basic)	-5.63
EPS (diluted)	-5.66
FCF / Share	-4.00

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	4.63M
Short Ratio	2.02
Short % of Float	8.94%
Beta	1.83

PE Ratio	n/a
Forward PE	n/a
P/FCF Ratio	n/a
PS Ratio	967.17
PB Ratio	14.19
Revenue	12.40M
Operating Income	-283.18M
Net Income	-276.96M
Free Cash Flow	-212.26M

Net Cash	847.01M
Net Cash / Share	15.88
Gross Margin	-1,823.96%
Operating Margin	-2,283.70%
Profit Margin	n/a
FCF Margin	-1,711.76%
ROA	-23.07%
ROE	-42.70%
ROIC	-83.70%

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy	0
Overweight	0
Hold	6
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: Hold

Price Target

$215.00*

(-4.41% downside)

Low

135

Current: $224.91

High

225

Target: 215.00

*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Income Statement | Balance Sheet | Cash Flow | Ratios

Year	2019	2018	2017	2016	2015	2014	2013
Revenue	-	33.56	11.44	41.97	14.20	5.92	-
Revenue Growth	-	193.29%	-72.74%	195.59%	140.01%	-	-
Gross Profit	-	33.56	11.44	41.97	14.20	5.92	-
Operating Income	-288	-73.65	-58.67	-10.53	-23.21	-17.22	-13.63
Net Income	-276	-67.70	-57.01	-10.38	-22.95	-16.83	-12.70
Shares Outstanding	44.77	38.39	32.83	27.48	6.29	1.76	1.17
Earnings Per Share	-6.17	-1.76	-1.74	-0.38	-4.48	-11.30	-11.98
Operating Cash Flow	-242	-64.82	-9.84	-20.86	-32.10	13.66	-12.53
Capital Expenditures	-3.26	-3.37	-1.51	-1.08	-1.31	-0.72	-1.17
Free Cash Flow	-245	-68.19	-11.35	-21.94	-33.41	12.94	-13.70
Cash & Equivalents	418	317	257	140	112	43.65	1.91
Total Debt	0.38	-	-	-	-	-	-
Net Cash / Debt	418	317	257	140	112	43.65	1.91
Assets	456	407	283	201	117	46.89	4.70
Liabilities	49.82	36.69	52.13	55.92	22.71	32.21	2.56
Book Value	406	371	231	145	93.87	-36.91	-17.25

Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name	MyoKardia, Inc.
Country	United States
Employees	318
CEO	Anastasios E. Gianakakos

Stock Information

Ticker Symbol	MYOK
Stock Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
Unique Identifier	NASDAQ: MYOK
IPO Date	October 29, 2015

Description

MyoKardia, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.